JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Aktien・Fate Therapeutics Inc

Fate Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

0.92

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.89

Max

0.96

Schlüsselkennzahlen
By Trading Economics
Einkommen	15M -38M
Verkäufe	-231K 1.6M
Gewinnspanne	-2,309.454
Angestellte	181
EBITDA	4.3M -38M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+397.83% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	18. Aug. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.1M 122M
Vorheriger Eröffnungskurs	0.92
Vorheriger Schlusskurs	0.92

Nachrichtenstimmung

By Acuity

27%

73%

62 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

0.9101 / 1.14 Unterstützung & Widerstand

Fate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2025, 17:49 UTC

Wichtige Markttreiber

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. Aug. 2025, 17:18 UTC

Wichtige Markttreiber

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. Aug. 2025, 16:25 UTC

Ergebnisse

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. Aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. Aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. Aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. Aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement 2Q Rev $25.8M >EXOD

11. Aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. Aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. Aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. Aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. Aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. Aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. Aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. Aug. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. Aug. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Says Sabadell Offer Remains in Effect

11. Aug. 2025, 16:26 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Announced TSB Sale on July 1

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer-Vergleich

Kursveränderung

Fate Therapeutics Inc Prognose

Kursziel

By TipRanks

397.83% Vorteil

12-Monats-Prognose

Durchschnitt 4.58 USD 397.83%

Hoch 12 USD

Tief 1 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fate Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Fate Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

0.9101 / 1.14Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Stimmung

By Acuity

62 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.